Alnylam Buoyed By Early Alzheimer’s Gene Silencing Success
Targets Early Disease-Causing Protein
Executive Summary
Alnylam has unveiled Phase I data showing its RNAi candidate can eliminate the amyloid precursor protein in the brain – opening the door to treating Alzheimer’s and many more CNS diseases.
You may also be interested in...
Lilly’s Donanemab Slows Cognitive Decline; FDA Filing Imminent
The company’s anti-amyloid antibody succeeded in Phase III with efficacy at least on par with Eisai/Biogen’s Leqembi, but with ARIA-related deaths unseen with the rival therapy.
Biogen Drug Sends Tau Into Reverse: An Alzheimer’s Breakthrough In The Making?
Phase I study and open-label extension results show a big drop in tau levels, which are more closely linked to Alzheimer’s symptoms than amyloid beta – setting up hopes of success in an ongoing Phase II study.
Alnylam Replaces Sanofi Partnership With Second Regeneron Tie-Up For RNAi Drugs
Already partnered with Regeneron in NASH, Alnylam unveils a new R&D collaboration in eye, CNS and liver indications, after Alnylam and Sanofi end the research phase of their relationship.